11-01-2018 дата публикации
Номер: US20180009892A1
Принадлежит:
The invention relates to antibodies, and in particular, to antibodies exhibiting specificity for Receptor tyrosine kinase-like Orphan Receptors (ROR), and to uses thereof, for example in the treatment of cancer. The invention extends to polynucleotide and polypeptide sequences encoding the antibodies, and therapeutic uses thereof, and to diagnostic kits comprising these molecules. The invention also extends to antibody-drug conjugates and to uses thereof in therapy. 144.-. (canceled)45. A polypeptide capable of binding to Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1) protein , the peptide comprising an amino acid sequence selected from a group consisting of:(i) SEQ ID NO:8, 9, 10, 16, 17 and/or 18;(ii) SEQ ID NO:24, 25, 26, 32, 33 and/or 34;(iii) SEQ ID NO:40, 41, 42, 48, 49 and/or 50;(iv) SEQ ID NO:56, 57, 58, 64, 65 and/or 66;(v) SEQ ID NO:72, 73, 74, 80, 81 and/or 82;(vi) SEQ ID NO:88, 89, 90, 96, 97 and/or 98;(vii) SEQ ID NO:104, 105, 106, 112, 113 and/or 114;(viii) SEQ ID NO:120, 121, 122, 128, 129 and/or 130;(ix) SEQ ID NO:136, 137, 138, 144, 145 and/or 146;(x) SEQ ID NO:152, 153, 154, 160, 161 and/or 162;(xi) SEQ ID NO:168, 169, 170, 176, 177 and/or 178;(xii) SEQ ID NO:184, 185, 186, 192, 193 and/or 194;(xiii) SEQ ID NO:200, 201, 202, 208, 209 and/or 210; and/or(xiv) SEQ ID NO:216, 217, 218, 224, 225 and/or 226.46. The polypeptide of claim 45 , comprising a functional fragment of an anti-ROR1 antibody.47. The polypeptide of claim 46 , comprising an anti-ROR1 scFv.48. The polypeptide of claim 45 , comprising at least two claim 45 , three claim 45 , four claim 45 , five or six amino acid sequences defined in any of (i) to (xiv).49. The polypeptide according to claim 45 , wherein the peptide comprises an amino acid sequence substantially as set out in SEQ ID NO: 4 claim 45 , 20 claim 45 , 36 claim 45 , 52 claim 45 , 68 claim 45 , 84 claim 45 , 100 claim 45 , 116 claim 45 , 132 claim 45 , 148 claim 45 , 164 claim 45 , 180 claim 45 , 196 or 212 claim 45 , ...
Подробнее